Clinical trials: Lung Cancer
Carcinoma, Non-Small-Cell Lung
Dose Escalating Study of the Safety and Efficacy of Patupilone, q3w, in Patients With Non-small Cell Lung Cancer
The study objective is to evaluate the maximum tolerated dose, safety and efficacy of patupilone in patients with NSCLC who have progressed after prior chemotherapy.
- Trial name
- NCT00171834
- Testing
- Patupilone
- Where
- 4 sites in United States
- Volunteers
- 89 people
- Sponsor
- Novartis Pharmaceuticals
Brain Metastases From Non-small Cell Lung Cancer
Comparison of Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Adults With Brain Metastases From Non-Small Cell Lung Cancer
The primary objective of this study is to evaluate the efficacy and safety of veliparib and whole brain radiation therapy in adults with brain metastases from non-small cell lung cancer (NSCLC).
- Trial name
- NCT01657799
- Testing
- Veliparib, Whole brain radiation therapy
- Volunteers
- 307 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Brain and Central Nervous System Tumors, Intraocular Melanoma
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 monoclonal antibody 3F8, can find tumor cells and carry tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin)
- Trial name
- NCT00445965
- Testing
- DNA analysis, immunologic technique, pharmacological study
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL)
A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer
The purpose of this clinical study is to establish the safety profile, determine the maximum tolerated dose (MTD) and recommend a Phase 2 dose and schedule of SRA737; and to evaluate the efficacy of SRA737 in…
- Trial name
- NCT02797964
- Testing
- SRA737
- Where
- 15 sites in United Kingdom
- Volunteers
- 107 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Segmentectomy
Comparison of Energy Instruments and Stapling Device to Dissect Intersegmental Plane in Segmentectomy
According to published studies, there are two main approaches in the dissection of intersegmental plane: stapling devices and energy instrument separation.
- Trial name
- NCT03192904
- Testing
- Energy Instruments, Stapling Device
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Ruijin Hospital
Carcinoma, Non-Small-Cell Lung
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
The purpose of this study is to compare the efficacy, as demonstrated by progression-free survival (PFS), in participants treated with amivantamab in combination with chemotherapy, versus chemotherapy alone in participants with…
- Trial name
- PAPILLON (NCT04538664)
- Testing
- Amivantamab, Pemetrexed, Carboplatin
- Where
- 232 sites in United States, Australia and 24 more
- Volunteers
- 308 people
- Sponsor
- Janssen Research & Development, LLC
Seriously Ill Patients, Cancer
Goals of Care Conversations Study
The long term goal is to improve quality of care in Veterans with serious illnesses by aligning medical care with Veterans' goals and values.
- Conditions
- Seriously Ill Patients, Cancer, Heart Failure, Interstitial Lung Disease
- Trial name
- LSTDI (NCT05001009)
- Testing
- Clinician Implementation Strategy Stage 1: low intensity clinician training, Clinician Implementation Strategy Stage 2: high intensity clinician training, Low patient engagement
- Where
- 3 sites in United States
- Volunteers
- 2,859 people
- Sponsor
- VA Office of Research and Development
Non-Small Cell Lung Cancer
Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC
The proposed study will evaluate the safety and feasibility of preoperative administration nivolumab +/- ipilimumab in patients with high-risk resectable NSCLC, and will facilitate a comprehensive exploratory characterization of…
- Trial name
- NA_00092076 (NCT02259621)
- Testing
- Nivolumab, Carboplatin, Paclitaxel
- Where
- 5 sites in United States, Canada
- Volunteers
- 39 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Advanced Solid Tumors
A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors
The purpose of this study is to find a safe, tolerable, and efficacious dose of BMS-986466 when given orally, in combination with adagrasib with or without cetuximab in participants with advanced KRAS G12C-mutant non-small cell…
- Trial name
- NCT06024174
- Testing
- BMS-986466, Adagrasib, Cetuximab
- Where
- 9 sites in United States, Australia and 3 more
- Volunteers
- 5 people
- Sponsor
- Bristol-Myers Squibb
Malignant Pleural Effusion, Recurrent Non-small Cell Lung Cancer
Imatinib Mesylate and Paclitaxel in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
This phase II trial is studying how well giving imatinib mesylate together with paclitaxel works in treating older patients with stage IIIB or stage IV non-small cell lung cancer.
- Conditions
- Malignant Pleural Effusion, Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00408460
- Testing
- imatinib mesylate, paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- University of Washington
Non-Small-Cell Lung Carcinoma, Adenocarcinoma
A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.
To determine if the addition of AG-013736 to chemotherapy is beneficial in patients with advanced lung cancer who have not been previously treated.
- Trial name
- NCT00600821
- Testing
- Bevacizumab, Carboplatin, Paclitaxel
- Where
- 44 sites in United States, Czechia and 4 more
- Volunteers
- 118 people
- Sponsor
- Pfizer
Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma
Azacitidine and Entinostat in Treating Patients With Stage I Non-Small Cell Lung Cancer That Has Been Removed By Surgery
This study combines the deoxyribonucleic acid (DNA) methyltransferase inhibitor, 5-azacitidine (5-AZA), with an orally bioavailable histone deacetylase inhibitor, entinostat (SNDX-275), for the adjuvant treatment of patients with…
- Trial name
- NCT01207726
- Testing
- Azacitidine, Entinostat, Laboratory Biomarker Analysis
- Where
- 9 sites in United States
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
Non-Squamous Non-Small Cell Lung Cancer
AVAPERL1 Study: A Study of Avastin (Bevacizumab) With or Without Pemetrexed as Maintenance Therapy After Avastin in First Line in Patients With Non-Squamous Non-Small Cell Lung Cancer
This open-label study will assess the efficacy and safety of Avastin with or without pemetrexed as maintenance therapy in patients with advanced, metastatic or recurrent non-small cell lung cancer.
- Trial name
- NCT00961415
- Testing
- bevacizumab [Avastin], cisplatin, pemetrexed
- Where
- 91 sites in France, Germany and 10 more
- Volunteers
- 376 people
- Sponsor
- Hoffmann-La Roche
Lung Cancer
Proton Radiotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC)
The goal of this clinical research study is to learn if escalated/accelerated proton radiotherapy can improve the control of Non-Small Cell Lung Cancer (NSCLC) and decrease side effects.
- Trial name
- NCT00495040
- Testing
- Proton Radiotherapy
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- M.D. Anderson Cancer Center
Cachexia, Non-Small-Cell Lung Cancer
Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia.
Study to assess the safety and tolerability of repeated doses of an investigational new drug in patients with cancer and cachexia.
- Conditions
- Cachexia, Non-Small-Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer
- Trial name
- NCT04299048
- Testing
- PF-06946860
- Where
- 10 sites in United States
- Volunteers
- 11 people
- Sponsor
- Pfizer
Smoking, Cigarette, Breastfeeding
Lung and Breast Cancer Prevention by an Integrated Intervention of Maternal Smoking Cessation and Breastfeeding
This pilot clinical trial aims to integrate maternal smoking cessation and breastfeeding interventions to enhance both cancer prevention behaviors.
- Trial name
- NCT05123118
- Testing
- Integrated intervention of smoking cessation and breastfeeding
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Xiaozhong Wen
Lung Cancer, Non-Small Cell
Study to Test the Efficacy of the Vaccine GSK 249553 in Treating Non-small-cell Lung Cancer After Tumour Removal by Surgery
Patients will receive injections of GSK 249553 vaccine . Appropriate tests will be performed to assess the safety of the treatment and its ability to induce an immune response.
- Trial name
- NCT00290355
- Testing
- GSK 249553 vaccine
- Where
- 62 sites in Belgium, Estonia and 12 more
- Volunteers
- 182 people
- Sponsor
- GlaxoSmithKline
Lung Cancer
A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer
The goal of Part 1 of this clinical research study is to find the highest dose of (Imbruvica) ibrutinib that can be given to patients with non-small cell lung cancer (NSCLC).
- Trial name
- NCT02321540
- Testing
- Ibrutinib
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Neoplasms, Lung Neoplasms
A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)
Background: Two experimental drugs, FdCyd (also called 5-fluoro-2'-deoxcytidine), and THU (also called tetrahydrouridine), are undergoing trials to test their effectiveness in treating cancer that has not responded to standard…
- Conditions
- Head and Neck Neoplasms, Lung Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms
- Trial name
- NCT00978250
- Testing
- 5-Fluoro-2'-Deoxycytidine (FdCyd) + Tetrahydrouridine (THU)
- Where
- 4 sites in United States
- Volunteers
- 95 people
- Sponsor
- National Cancer Institute (NCI)
Non Small Cell Lung Cancer, NSCLC
EBUS-Miniforceps Biopsy Specimen Acquisition for PD-L1 Testing in Nonsmall Cell Lung Cancer
The incorporation of PD-L1 testing into clinical practice has progressed at a rapid pace, and now offers an additional line of therapy for eligible patients with nonsmall cell lung cancer.
- Trial name
- NCT04159025
- Testing
- CoreDx Pulmonary Mini-Forceps
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.